Brief Summary of Minutes of Annual Meeting

• Fenbendazole for pheasants  
• TAS: complete
• HFS: complete (except for tox piece);
• Effectiveness: outstanding—completed in 2000; must re-affirm data with white paper; goal is that by the end of this calendar year to be submitted;
• Environmental impact: initially wanted to ask for categorical exclusion from the EA, that request rejected; Eric Rosenblum will put together an exposure assessment report, including relevant information on how pheasants are managed, where leftover feed goes, etc.
• Fenbendazole for quail
• Effectiveness: (a) farmed quail- completed back in 2000, would need to re-affirm; (b) free-ranging quail- recent study completed, submission being prepared
• TAS: recent study completed, study designed to cover both farmed and free-ranging quail, submission being prepared
• Environmental impact/free-ranging quail: Planning a categorical exclusion request (regs say that if the drug is already approved in a species that has similar animal management practices, the proposed new use can be excluded from having to provide an EA).
• Human food safety: method/validation is currently under review; residue depletion study completed, final study report undergoing QA review
• The indication for the free-ranging quail = Lots of stakeholders! Lots of resources towards combatting the decrease of quail – especially in Texas !
• Erythromycin in salmon
• New sponsor to work on CMC technical section; will require a new API (active pharmaceutical ingredient)
• Still working with Chris Moffitt as conduit between manufacturer and end-users;
• Effectiveness: TS complete in 2000, when asked for re-affirmations in 2012-13 claim for all salmonids came back as chinook only; ONADE recommended we do another study; hope to write justification
• TAS:  TS complete in 2000, when asked for re-affirmations in 2012-13 claim for all salmonids came back as chinook only;
• Have had conversations with ONADE about going back to all salmonids for both EFF and TAS TSs, but with new API, calling into question EVERYTHING;
• Environmental impact: EA completed back when previous sponsor was involved;  will need to be revised based on removal of proprietary information
• Strontium chloride in salmon
• TAS:  Rod did TAS study (submitted in Jan 2016; incomplete); TAS will be submitted by the end of the year;
• Effectiveness, environmental, HFS:  white paper arguments for the rest of the TS; lots of data from the public domain—i.e. public health organizations
• Ivermectin block in cattle
• Collaboration between= (Texas cattle fever tick, USDA/ARS/APHIS, state veterinary, Postive Feeds)
• Project was deemed minor use bc it was geographically contained to a small area to eradicate cattle fever tick; this product is not intended to be used outside the quarantine zone
• TAS, HFS, environmental, effectiveness:  No progress on any of the technical sections
• Postive Feeds has made no progress on the CMC technical section.  Have recommended that they seek advice from a manufacturing consultant.
• Is there an option for another legal status? Perhaps legal compounding?
• Dr. Baca, our USDA contact down in Texas, recently retired; Amy needs to contact Dr. Hallie Hassel
• Need to have an action plan for this project
• APHIS will likely want to continue this if at all possible; Mexico has seen ivermectin resistance and tick is spreading along the edges of the quarantine zone
• CIDR in goats
• TAS, HFS, environmental: 3 TS COMPLETE
• Effectiveness: did complete effectiveness studies but lots of data errors
• Write up on the data from the farms that we do have; explain why other farms left out
• Zoetis approved for use in sheep and goats in other countries
• Not used in dairy goats